We Accept Insurance!

Spravato® for Depression Relief.

Spravato® for Depression Relief.

Unlock healing with FDA-approved esketamine treatment.

Spravato® (esketamine) is a nasal spray prescribed for treatment-resistant depression. Unlike oral antidepressants, which take weeks to months to work, the healing effects of Spravato® are typically felt within hours. Patients feel better, and get back to living the life they want to live, faster.  Get a treatment that works when other medications have failed. Rediscover yourself with Spravato®.

Convenient and personalized expert care for your healing.

1. Connect with care.

At Heading, we offer Spravato® treatment to patients who qualify under their insurance plan and in accordance with FDA’s safety requirements. 


Most insurance companies require at least two prior antidepressant trials, and for patients to be taking an oral antidepressant during the course of treatment.

2. Meet your team.

Visit with your Heading care team virtually for initial appointment and treatment planning. 

During this 1-hour session, you and a Heading clinician will discuss your history, current symptoms, and treatment options, including Spravato®. 

3. Focus on healing.

Appointments are typically twice weekly for the first month, and once weekly for the second month. Treatment is under the supervision of your prescriber — then you’ll sit back, relax, and allow the effects to unfold. Sessions are about two hours.


After treatment, if you are also being seen by a Heading therapist, at your next therapy session you may process and integrate the experience and set intentions for continued treatment.

The Science Behind Esketamine Treatment

Spravato® targets the glutamate system in the brain, which plays an important role in healthy brain functioning. Glutamate is a highly abundant neurotransmitter, responsible for facilitating signals between nerve cells. This process works with different pathways in the brain than traditionally prescribed medications, and often relief begins to be felt more quickly.

Research and understanding of this new approach for depression is continuing to deepen. It’s thought to create new connections in the brain, allowing for behavioral and cognitive changes to occur more readily and rapidly in patients with treatment-resistant depression. Clinical trials have shown over 60% response rate, and 52% remission rate in patients treated with Spravato® with minimal side effects. 

Take the first step

Want to find out if Heading is right for you?

Complete our consultation form and an intake specialist will reach out. You can also schedule a call from us when it’s best for you.


Schedule your consultation